Login to Your Account

Transcept, ARCA: Where Are They Now?

Reverse Merger Interest Dims As IPO Window Creaks Open

By Jennifer Boggs

Monday, February 28, 2011
Back before Ironwood Pharmaceuticals Inc. showed the world that biotechs could make a go at initial public offerings (IPO), the reverse merger temporarily shed its less-than-desirable reputation. It became the exit du jour for private biotechs whose IPO bids were stymied by unfavorable market conditions and needed access to substantial cash.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription